These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21752176)

  • 1. 'I am not going to live to regret that, am I?' A pseudo-hepatocellular carcinoma case.
    Abbass K; Markert RJ; Kaplon MK
    Liver Int; 2011 Oct; 31(9):1418. PubMed ID: 21752176
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
    Irtan S; Chopin-Laly X; Ronot M; Faivre S; Paradis V; Belghiti J
    Liver Int; 2011 May; 31(5):740-3. PubMed ID: 21457447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
    Novi M; Lauritano EC; Piscaglia AC; Barbaro B; Zocco MA; Pompili M; Gasbarrini A
    Am J Gastroenterol; 2009 Jul; 104(7):1852-4. PubMed ID: 19574982
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib use in hepatocellular carcinoma: more questions than answers.
    Abou-Alfa GK
    Hepatology; 2014 Jul; 60(1):15-8. PubMed ID: 24493250
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
    Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.
    Bettinger D; Schultheiss M; Knüppel E; Thimme R; Blum HE; Spangenberg HC
    Hepatology; 2012 Aug; 56(2):789-90. PubMed ID: 22307848
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma.
    Zhao Y; Yang M; Qi X; Han G; Fan D
    Hepatology; 2012 Aug; 56(2):790-1. PubMed ID: 22307917
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib in clinical practice: evidence-based use or abuse?
    Basso M; Basso M; Barone C
    Hepatology; 2012 Apr; 55(4):1305; author reply 1305-6. PubMed ID: 22189632
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 10. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
    Chan SL; Johnson P
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):111-4. PubMed ID: 22524569
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hepatocellular carcinoma].
    Kudo M
    Nihon Geka Gakkai Zasshi; 2011 Mar; 112(2):122-9. PubMed ID: 21488346
    [No Abstract]   [Full Text] [Related]  

  • 12. Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.
    Subramanian M; Singal AG; Yopp AC
    Clin Gastroenterol Hepatol; 2012 Oct; 10(10):e83-4. PubMed ID: 22813441
    [No Abstract]   [Full Text] [Related]  

  • 13. Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
    Wu SS; Yen HH; Chung CY
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):566-7. PubMed ID: 18555670
    [No Abstract]   [Full Text] [Related]  

  • 14. A maxillary mass in a HBV-cirrhotic patient.
    Nguyen V; George J; van der Poorten D
    Liver Int; 2012 Jul; 32(6):988. PubMed ID: 22380542
    [No Abstract]   [Full Text] [Related]  

  • 15. Closing remarks.
    Kudo M
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():52. PubMed ID: 22873627
    [No Abstract]   [Full Text] [Related]  

  • 16. [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
    Ishizaki M; Kaibori M; Matsui K; Yanagimoto Y; Nakatake R; Kwon AH
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2679-82. PubMed ID: 21224678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
    Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
    Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

  • 19. Major achievements in hepatocellular carcinoma.
    Bruix J; Llovet JM
    Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
    Kitajima T; Hatano E; Mitsunori Y; Taura K; Fujimoto Y; Mizumoto M; Okajima H; Kaido T; Minamiguchi S; Uemoto S
    Clin J Gastroenterol; 2015 Oct; 8(5):300-5. PubMed ID: 26249525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.